References
- 1. 1.Nicolas D, Kerndt CC, Reed M. Sacubitril/Valsartan. [Updated 2020 Dec 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK507904/
- 2. ENTRESTO Rezumatul Caracteristicilor Produsului 2019.
- 3. 3.Senni M, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep;18(9):1193-202. doi: 10.1002/ejhf.548.10.1002/ejhf.548508481227170530
- 4. Rohde LE, Chatterjee NA, Vaduganathan M, Claggett B, Packer M, Desai AS, Zile M, Rouleau J, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Sacubitril/Valsartan and Sudden Cardiac Death According to Implantable Cardioverter-Defibrillator Use and Heart Failure Cause: A PARADIGM-HF Analysis. JACC Heart Fail. 2020 Oct;8(10):844-855. doi: 10.1016/j.jchf.2020.06.015. Epub 2020 Sep 9. PMID: 32919916.10.1016/j.jchf.2020.06.01532919916
- 5. Selvaraj S, Claggett BL, Pfeffer MA, Desai AS, Mc Causland FR, McGrath MM, Anand IS, van Veldhuisen DJ, Kober L, Janssens S, Cleland JGF, Pieske B, Rouleau JL, Zile MR, Shi VC, Lefkowitz MP, McMurray JJV, Solomon SD. Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF. Eur J Heart Fail. 2020 Nov;22(11):2093-2101. doi: 10.1002/ejhf.1984. Epub 2020 Sep 30. PMID: 32840930.10.1002/ejhf.198432840930
- 6. Novartis; PARAGON-HF ClinicalTrials.gov number, NCT01920711.
- 7. PROVE-HF, ClinicalTrials.gov number, NCT02887183
- 8. Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.